Skip to content
General News, Medical Health Aged Care

Tasmania lightens the overload of Australia’s most common genetic disorder

Haemochromatosis Australia 2 mins read

MEDIA RELEASE Embargo until June 1, 2023 at 12.00am EST

Tasmanian landmarks along with around 100 well-known buildings and landmarks across Australia will turn red every evening from 1-7 June, shining a light on an extremely common genetic condition that most people have never heard of.

It is part of a worldwide initiative to raise awareness of haemochromatosis – also known as iron overload – and to prompt people to get tested. Most people know that having too little iron in your body can cause anaemia, which is characterised by tiredness and lethargy, but few people know that the same symptoms can also be caused by having too much iron.

The hereditary condition, which is passed on from both biological parents, is simple to detect and treat but if undiagnosed or ignored can lead to serious and life-threatening illness, including liver disease and diabetes. One in seven Australians carry one copy of the defective gene, while and one in 200 Australians have two copies, which puts them at high risk of developing the condition.

Dr Dan Johnstone, an iron researcher who also has the condition, says early detection is key to minimising or preventing permanent damage. “Awareness of haemochromatosis is more important now than ever as early diagnosis will help save lives, cut health costs and reduce unnecessary suffering for so many individuals and families. Everybody is different; some people will have early symptoms of fatigue or joint aches while others won’t know they have the condition until the damage is already done. Anyone who suspects they may have this condition should ask their GP for a blood test. Haemochromatosis is not a burden in your life if you get on to it early. Early diagnosis is key to managing and reducing complications. It is usually managed by a regime of therapeutic blood donations, at an Australian Red Cross Lifeblood donor centre. This is a classic win-win situation, benefiting both the individual and the community,” said Dr Johnstone.

Haemochromatosis Australia spokesperson, Tony Moorhead, said, “Despite being the most common genetic disorder in Australia, haemochromatosis is often underdiagnosed because people don’t know about it and symptoms are non-specific. Unfortunately, most of those affected aren’t diagnosed until aged in their mid-forties and already suffering ill health. “There are people with the condition who should have been diagnosed decades earlier. This would have reduced the suffering, medical cost and even loss of life that results from iron overload. If haemochromatosis is detected early enough it is completely preventable – those affected need never get sick, they simply need to donate blood to maintain normal iron levels and their health.” Mr Moorhead says. “Hereditary haemochromatosis is estimated to cost Australia’s health system about $280 million annually and to add further cost burdens by compounding other chronic conditions.” Haemochromatosis is easy to test, simple to treat but tragic to ignore. -

 

ENDS Landmarks lighting up can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 


Key Facts:

* Australia's most common genetic disorder, that most have never heard of

* World Haemochromatosis Awareness Week June 1 - 7 

* Landmarks lighting up in red can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 


About us:

To find out more visit www.ha.org.au/haemochromatosis


Contact details:

Media enquiries:

Kellie Curtain M: 0412339690 kellie@indeliblemarks.net.au 

More from this category

  • General News
  • 08/10/2024
  • 22:11
EnviroGold Global Limited

EnviroGold Global Closes Final Tranche of Upsized Private Placement

TORONTO, Oct. 08, 2024 (GLOBE NEWSWIRE) -- EnviroGold Global Limited (CSE: NVRO | OTCQB: ESGLF | FSE: YGK) (“EnviroGold,” or the “Company”), a technology company enabling the global mining industry to monetize valuable metals contained in mine waste and tailings, reduce environmental liabilities and improve social and environmental outcomes, is pleased to announce that it has closed the fourth and final tranche of its previously announced non-brokered private placement (the “Financing”) and issued 17,310,900 units (the “Units”) at a price of $0.05 per Unit for aggregate gross proceeds of $865,545. Each Unit consists of one common share (each, a “Common…

  • Medical Health Aged Care
  • 08/10/2024
  • 21:11
Invivoscribe

EU Notified Body (BSI Netherlands) and the EMA Grant Approval of the LeukoStrat® CDx FLT3 Mutation Assay for VANFLYTA® Therapy in the EU and EEA

SAN DIEGO–BUSINESS WIRE– Invivoscribe is excited to announce that their CE-2797 IVD certified LeukoStrat® CDx FLT3 Mutation Assayhas been approved by BSI (Netherlands) and…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 08/10/2024
  • 16:19
Public Health Association of Australia

PHAA thanks Professor Paul Kelly, outgoing Chief Medical Officer, for his commitment to public health

8 October 2024 The Public Health Association of Australia (PHAA) acknowledges the contribution of Professor Paul Kelly as he announces his departure from the role of Chief Medical Officer of Australia (CMO) and Director of the Interim Centre for Disease Control. Professor Kelly commenced as Deputy CMO in January 2020 as COVID-19 was emerging. He became acting CMO in July 2020 and was appointed CMO in January 2021. “A public health physician and infectious disease epidemiologist, Professor Kelly was the right man to offer leadership to Australia during the COVID-19 pandemic,” said PHAA CEO, Adjunct Professor Terry Slevin. “Few people…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.